PDCD1 and gastric cancer: The anti-PD-1 antibody nivolumab plus regorafenib (a VEGFR1-3 inhibitor) achieved an ORR of 44% (5/9) in patients with pretreated GC in REGNIVO study [11], which provides a rationale for the application of immunotherapy combined with antiangiogenic agents in gastric or esophagogastric junction cancer (GC/EGJC).